Bayesian Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History
Bayesian Capital Management, LP
- $788 Million
- Q4 2024
A detailed history of Bayesian Capital Management, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Bayesian Capital Management, LP holds 25,700 shares of VRDN stock, worth $396,551. This represents 0.06% of its overall portfolio holdings.
Number of Shares
25,700
Previous 12,900
99.22%
Holding current value
$396,551
Previous $293,000
67.92%
% of portfolio
0.06%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$70.9 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$69.8 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$59.9 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$54.4 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $615M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...